Chemokine ligand 2: beyond chemotaxis-a multifaceted role in tumor progression.

Front Immunol · 2025 · PMC12669185 · PMID 41341593

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

In a phase II trial in metastatic castration-resistant prostate cancer ( NCT00992186 ), free CCL2 showed a trend of rapid rebound despite a manageable safety profile ( 223 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.